Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31298039 | 0.93 | HSD17B10 (0.57) | HSD17B10SIGMAR1HRH3 | |
| SCHEMBL31298041 | 0.91 | HSD17B10 (0.60) | HSD17B10SIGMAR1HRH3 | |
| SCHEMBL4023110 | 0.88 | HSD17B10 (0.42) | HSD17B10SIGMAR1HRH3ACE2KCNH2 | |
| SCHEMBL4024810 | 0.86 | HSD17B10 (0.41) | HSD17B10SIGMAR1HRH3KCNH2PAOX | |
| SCHEMBL1306555 | 0.86 | HSD17B10 (0.46) | HSD17B10SIGMAR1HRH3KCNH2PAOX | |
| SCHEMBL7092659 | 0.86 | HSD17B10 (0.41) | HSD17B10SIGMAR1HRH3ACE2KCNH2 | |
| SCHEMBL4915224 | 0.86 | GNAI3 (0.44) | HSD17B10SIGMAR1HTR1A | |
| SCHEMBL4024813 | 0.84 | HSD17B10 (0.44) | HSD17B10SIGMAR1HRH3KCNH2PAOX | |
| SCHEMBL4901796 | 0.84 | GNAI3 (0.52) | HSD17B10KCNH2HTR1A | |
| SCHEMBL21084328 | 0.83 | GNAI3 (0.55) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1057815-B1 | CYCLIC AMIDE COMPOUNDS | KOWA CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-6645957-B2 | Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis | KOWA CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-20030096828-A1 | Cyclic amide compound | KOWA CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-6448242-B1 | COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS | KOWA CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-1057815-A1 | CYCLIC AMIDE COMPOUNDS | Kowa Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096828-A1 | Cyclic amide compound | CMA1, HRH2, HRH4 | HSD17B10 3028/4885SIGMAR1 1368/4885HRH3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.